AU2013242492B2 - Bicyclic pyrazinone derivatives - Google Patents

Bicyclic pyrazinone derivatives Download PDF

Info

Publication number
AU2013242492B2
AU2013242492B2 AU2013242492A AU2013242492A AU2013242492B2 AU 2013242492 B2 AU2013242492 B2 AU 2013242492B2 AU 2013242492 A AU2013242492 A AU 2013242492A AU 2013242492 A AU2013242492 A AU 2013242492A AU 2013242492 B2 AU2013242492 B2 AU 2013242492B2
Authority
AU
Australia
Prior art keywords
denotes
phenyl
unsubstituted
mmol
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013242492A
Other languages
English (en)
Other versions
AU2013242492A1 (en
Inventor
Hans-Peter Buchstaller
Dieter Dorsch
Gerard Moinet
Ansgar Wegener
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48013911&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013242492(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2013242492A1 publication Critical patent/AU2013242492A1/en
Application granted granted Critical
Publication of AU2013242492B2 publication Critical patent/AU2013242492B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013242492A 2012-03-28 2013-03-19 Bicyclic pyrazinone derivatives Active AU2013242492B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12002215 2012-03-28
EP12002215.7 2012-03-28
PCT/EP2013/000827 WO2013143663A1 (en) 2012-03-28 2013-03-19 Bicyclic pyrazinone derivatives

Publications (2)

Publication Number Publication Date
AU2013242492A1 AU2013242492A1 (en) 2014-11-13
AU2013242492B2 true AU2013242492B2 (en) 2016-12-15

Family

ID=48013911

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013242492A Active AU2013242492B2 (en) 2012-03-28 2013-03-19 Bicyclic pyrazinone derivatives

Country Status (31)

Country Link
US (1) US9120805B2 (https=)
EP (1) EP2831077B1 (https=)
JP (1) JP6096879B2 (https=)
KR (1) KR102070567B1 (https=)
CN (1) CN104169284B (https=)
AR (1) AR090496A1 (https=)
AU (1) AU2013242492B2 (https=)
CA (1) CA2868620C (https=)
CL (1) CL2014002557A1 (https=)
CO (1) CO7111292A2 (https=)
DK (1) DK2831077T3 (https=)
EA (1) EA027416B1 (https=)
EC (1) ECSP14024526A (https=)
ES (1) ES2585044T3 (https=)
HR (1) HRP20160908T1 (https=)
HU (1) HUE030067T2 (https=)
IL (1) IL234713A (https=)
MX (1) MX351149B (https=)
MY (1) MY172308A (https=)
NZ (1) NZ630489A (https=)
PE (1) PE20142186A1 (https=)
PH (1) PH12014501829B1 (https=)
PL (1) PL2831077T3 (https=)
PT (1) PT2831077T (https=)
RS (1) RS54997B1 (https=)
SG (1) SG11201405750YA (https=)
SI (1) SI2831077T1 (https=)
TW (1) TWI576346B (https=)
UA (1) UA112795C2 (https=)
WO (1) WO2013143663A1 (https=)
ZA (1) ZA201407828B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013132253A1 (en) 2012-03-07 2013-09-12 Institute Of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
CA2868620C (en) 2012-03-28 2020-02-25 Dieter Dorsch Bicyclic pyrazinone derivatives
EP2864330A1 (en) * 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG Pyrrolopyrazone inhibitors of tankyrase
EP3044221B1 (en) 2013-09-11 2018-02-21 Institute of Cancer Research: Royal Cancer Hospital (The) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
RU2672885C2 (ru) * 2013-12-23 2018-11-20 Мерк Патент Гмбх Производные имидазопиразинона
WO2016006974A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
KR101739003B1 (ko) 2014-07-11 2017-05-23 에스티팜 주식회사 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도
KR20160007347A (ko) 2014-07-11 2016-01-20 에스티팜 주식회사 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도
WO2016006975A2 (en) * 2014-07-11 2016-01-14 St Pharm Co., Ltd. Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
CN107278203B (zh) 2014-12-05 2020-05-19 阵列生物制药公司 作为JANUS激酶抑制剂的4,6-取代的吡唑并[1,5-a]吡嗪
CR20180168A (es) 2015-08-17 2018-06-27 Lupin Ltd Derivados de heteroarilo como inhibidores de parp
CN109071546B (zh) 2016-02-24 2021-03-02 辉瑞大药厂 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2019034973A1 (en) 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
EP3793559A1 (en) 2018-05-17 2021-03-24 Bayer Aktiengesellschaft Substituted dihydropyrazolo pyrazine carboxamide derivatives
GB2632307A (en) * 2023-08-02 2025-02-05 Duke Street Bio Ltd PARP1 inhibitor compounds
GB2632441A (en) * 2023-08-08 2025-02-12 Duke Street Bio Ltd Deuterated PARP1 inhibitor compounds
WO2025084446A1 (ko) * 2023-10-16 2025-04-24 에스티팜 주식회사 트리아졸로피리미디논 유도체의 결정형

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209523A1 (en) * 2006-05-31 2009-08-20 Philip Jones Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp)
US20110053929A1 (en) * 2007-07-11 2011-03-03 Bayer Schering Pharma Aktiengesellschaft Imidazo-, pyrazolopyrazines and imidazotriazines and their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CA2672860C (en) * 2006-12-28 2013-01-29 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
WO2009130231A1 (en) 2008-04-24 2009-10-29 Glaxo Group Limited Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
WO2009130232A1 (en) * 2008-04-24 2009-10-29 Glaxo Group Limited Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
JP5579724B2 (ja) 2008-10-17 2014-08-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ホスファチジルイノシトール−3−キナーゼ(pi−3キナーゼ)阻害剤としてのテトラ−アザ−複素環
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
US8450320B2 (en) * 2010-04-16 2013-05-28 Abbvie Inc. Pyrrolopyrazinone inhibitors of kinases
CN102229611B (zh) * 2011-04-26 2012-12-12 山东大学 2,6-二芳基吡唑并[1,5-a]吡嗪-4(5H)-酮化合物及其应用
CA2868620C (en) 2012-03-28 2020-02-25 Dieter Dorsch Bicyclic pyrazinone derivatives
EP2864330A1 (en) * 2012-06-20 2015-04-29 F. Hoffmann-La Roche AG Pyrrolopyrazone inhibitors of tankyrase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090209523A1 (en) * 2006-05-31 2009-08-20 Philip Jones Pyrrolo[1,2-A] Pyrazin-1(2H)-One and Pyrrolo[1,2-D][1,2,4]Triazin-1(2H)-One Derivatives as Inhibitors of Poly(Adp-Ribose)Polymerase (Parp)
US20110053929A1 (en) * 2007-07-11 2011-03-03 Bayer Schering Pharma Aktiengesellschaft Imidazo-, pyrazolopyrazines and imidazotriazines and their use

Also Published As

Publication number Publication date
PE20142186A1 (es) 2014-12-29
EA201401062A1 (ru) 2015-04-30
MX351149B (es) 2017-10-04
CA2868620C (en) 2020-02-25
CN104169284A (zh) 2014-11-26
MX2014011420A (es) 2014-11-25
ZA201407828B (en) 2015-12-23
WO2013143663A1 (en) 2013-10-03
PH12014501829A1 (en) 2014-11-10
KR102070567B1 (ko) 2020-01-29
TWI576346B (zh) 2017-04-01
DK2831077T3 (en) 2016-08-15
CO7111292A2 (es) 2014-11-10
KR20140140099A (ko) 2014-12-08
CN104169284B (zh) 2017-03-29
IL234713A (en) 2016-09-29
MY172308A (en) 2019-11-21
CL2014002557A1 (es) 2014-12-19
ECSP14024526A (es) 2015-09-30
PH12014501829B1 (en) 2014-11-10
CA2868620A1 (en) 2013-10-03
NZ630489A (en) 2016-04-29
HRP20160908T1 (hr) 2016-09-23
HUE030067T2 (en) 2017-04-28
EP2831077A1 (en) 2015-02-04
HK1203961A1 (en) 2015-11-06
JP6096879B2 (ja) 2017-03-15
US9120805B2 (en) 2015-09-01
TW201343650A (zh) 2013-11-01
SG11201405750YA (en) 2014-10-30
EA027416B1 (ru) 2017-07-31
AR090496A1 (es) 2014-11-19
SI2831077T1 (sl) 2016-09-30
EP2831077B1 (en) 2016-04-27
ES2585044T3 (es) 2016-10-03
AU2013242492A1 (en) 2014-11-13
PT2831077T (pt) 2016-08-12
PL2831077T3 (pl) 2016-10-31
RS54997B1 (sr) 2016-11-30
US20150057264A1 (en) 2015-02-26
UA112795C2 (uk) 2016-10-25
JP2015511609A (ja) 2015-04-20

Similar Documents

Publication Publication Date Title
AU2013242492B2 (en) Bicyclic pyrazinone derivatives
AU2013301870B2 (en) (Aza-)isoquinolinone derivatives
AU2013257018B2 (en) Pyrrolotriazinone derivatives
AU2013324681B2 (en) Quinazolinone derivatives as PARP inhibitors
DK2812323T3 (en) TETRAHYDRO-quinazolinone derivatives BY TANKERS AND PARPINHIBITORER
HK1203961B (en) Bicyclic pyrazinone derivatives
HK1209106B (en) (aza-)isoquinolinone derivatives
HK1205740B (en) Pyrrolotriazinone derivatives
HK1202551B (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)